Related Experiment Video
Updated: Aug 6, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeting TPX2 to Enhance Metastasis Control and Radiosensitivity in Esophageal Squamous Cell Carcinoma Through
Fang Meng1,2, Jiaru Hu3, Shiqiang Zhang2
1Department of Radiation and Oncology, The Second Affiliated Hospital of Soochow University, Institute of Radiation & Oncology, Soochow University, Suzhou, Jiangsu, 215006, China.
Background:
Esophageal squamous cell carcinoma (ESCC) faces challenges of metastasis and variable radiosensitivity. The role of Targeting Protein for Xenopus Kinesin-like Protein 2 (TPX2) in regulating these ESCC-related traits is unclear, needing investigation.
Objectives:
This study investigates the functional role of TPX2 in regulating metastasis and radiosensitivity in ESCC.
Materials And Methods:
Differential expression of TPX2 in ESCC versus normal tissues was verified using bioinformatics (The Cancer Genome Atlas Program, Gene Expression Omnibus) and experimental analyses (Immunohistochemistry, Western blot). ESCC cell lines with stable TPX2 overexpression were established to evaluate effects on migration (wound healing assay), invasion (Transwell assay), and radiotherapy response via colony formation and apoptosis assays. In vivo, xenograft and lung homing mouse models (n=5/group) were employed to assess tumor growth, metastatic potential, and radiosensitivity. Additionally, exosome-mediated TPX2 transfer and its impacts on recipient cells were examined.
Results:
TPX2 was significantly upregulated in ESCC tissues and cell lines. TPX2 overexpression enhanced in vitro cell migration, invasion, and radiosensitivity, while promoting in vivo metastasis and modulating radiation response. Exosome-mediated TPX2 transfer induced comparable aggressive phenotypes in recipient cells. Mechanistically, TPX2 activated the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway (p-AKT/AKT ratio increased by ~2.5-fold), which directly contributed to enhanced metastatic potential and altered radiosensitivity.
Conclusion:
TPX2 acts as a key regulator of malignant progression and therapeutic response in ESCC by promoting epithelial-mesenchymal transition and activating the PI3K/AKT pathway.
Insights
Targeting Protein for Xenopus Kinesin-like Protein 2 (TPX2) promotes esophageal squamous cell carcinoma (ESCC) metastasis and alters radiosensitivity. TPX2 activates the PI3K/AKT pathway, driving tumor progression and impacting treatment outcomes in ESCC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Esophageal squamous cell carcinoma (ESCC) is characterized by challenging metastasis and variable radiosensitivity.
- The specific role of Targeting Protein for Xenopus Kinesin-like Protein 2 (TPX2) in these ESCC traits remains largely unexplored.
- Understanding TPX2's function is crucial for developing targeted therapies for ESCC.
Purpose of the Study:
- To investigate the functional role of TPX2 in regulating metastasis and radiosensitivity in ESCC.
- To elucidate the molecular mechanisms by which TPX2 influences ESCC progression.
- To assess the therapeutic potential of targeting TPX2 in ESCC.
Main Methods:
- Bioinformatic and experimental validation of TPX2 differential expression in ESCC tissues and cell lines.
- In vitro assays (wound healing, Transwell, colony formation, apoptosis) to assess migration, invasion, and radiosensitivity in TPX2-overexpressing ESCC cells.
- In vivo mouse models (xenograft, lung homing) to evaluate tumor growth, metastasis, and radiosensitivity.
- Examination of exosome-mediated TPX2 transfer and its effects on recipient cells.
- Analysis of the PI3K/AKT signaling pathway activation.
Main Results:
- TPX2 is significantly upregulated in ESCC tissues and cell lines.
- TPX2 overexpression enhances ESCC cell migration, invasion, and radiosensitivity in vitro.
- TPX2 promotes in vivo metastasis and modulates radiation response, with exosome-mediated transfer inducing aggressive phenotypes.
- TPX2 activates the PI3K/AKT pathway, leading to increased metastatic potential and altered radiosensitivity.
Conclusions:
- TPX2 is a key regulator of malignant progression in ESCC.
- TPX2 promotes epithelial-mesenchymal transition and activates the PI3K/AKT pathway, contributing to enhanced metastasis.
- TPX2 influences therapeutic response, highlighting its potential as a therapeutic target in ESCC.
